AP Desk 04 of 05
China, India, Japan, Korea, Southeast Asia and Australia: generic launches, patent dates, regulators, plants and fast-growing makers.
10 stories
KRSouth KoreaResearch
Daewon Pharmaceutical says its oral semaglutide candidate DW5324 reached 1.90 to 3.14 times the exposure of Rybelsus in two crossover studies of 18 and 19 people, presented at AAPS PharmSci 360.
CNChinaMoney
Gilead agreed to buy PepStar's oral IL-23R peptide program, led by Phase 1 candidate HCXT-2001, for $1.275 billion upfront in cash, with closing expected in Q4 2026.
INIndiaMaking
Dr. Reddy's says it is on track to fix the semaglutide ingredient problem that halted pen supply in July, with relaunch in November depending on three validation batches.
LKSri LankaMaking
Sri Lanka's health ministry says the country's first insulin factory, built at Koggala for more than Rs. 3 billion, is complete and should start production in 2027 after validation.
CNChinaMaking
QL Biopharm signed on October 21, 2026 to build a recombinant protein drug research and production base in Wuxi for its monthly GLP 1 injection and oral peptide.
CNChinaMoney
Hybio forecasts nine month 2026 net profit of RMB 430 million to 450 million, up more than fivefold on peptide active ingredient sales, while a RMB 968 million placement for peptide line expansion expired.
KRSouth KoreaMoney
Samsung Peptide won 87.88% acceptance for its CHF 44.31 per share PolyPeptide offer; approvals, a board vote and settlement are still pending.
CNChinaRules
FDA added two Chinese GLP 1 ingredient makers to Import Alert 66-40, so all drugs from their sites can be detained at the US border.
CNChinaMarket
China is building its own semaglutide supply chain, ingredient to pen.
CNChinaRules
Drug makers are told to plan for fewer Chinese contract suppliers on US-funded work.
